R1 RCM - RCM Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCM shares.
View RCM analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued 1-year price targets for R1 RCM's stock. Their RCM share price forecasts range from $10.00 to $32.00. On average, they predict the company's stock price to reach $17.62 in the next twelve months. This suggests a possible upside of 78.7% from the stock's current price.
View analysts price targets for RCM or view top-rated stocks among Wall Street analysts.

R1 RCM's stock was trading at $25.49 at the beginning of 2022. Since then, RCM shares have decreased by 61.3% and is now trading at $9.86.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our RCM earnings forecast.

R1 RCM Inc. (NASDAQ:RCM) announced its earnings results on Tuesday, November, 8th. The healthcare provider reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.18. The healthcare provider earned $496 million during the quarter, compared to analyst estimates of $522.29 million. R1 RCM had a trailing twelve-month return on equity of 4.77% and a net margin of 0.93%.

R1 RCM updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.79 billion-$1.80 billion, compared to the consensus revenue estimate of $1.87 billion.

253 employees have rated R1 RCM Chief Executive Officer Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.99%), Vanguard Group Inc. (3.36%), Alliancebernstein L.P. (2.45%), State Street Corp (1.07%), Bank of New York Mellon Corp (0.99%) and Paradigm Capital Management Inc. NY (0.80%). Insiders that own company stock include Achi Series Lllp Tcp-Asc, Albert Rene Zimmerli, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Michael C Feiner and Richard B Jr Evans.
View institutional ownership trends.

Shares of RCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCM stock can currently be purchased for approximately $9.86.

R1 RCM (NASDAQ:RCM) has a market capitalization of $4.11 billion and generates $1.47 billion in revenue each year. The healthcare provider earns $97.20 million in net income (profit) each year or $0.06 on an earnings per share basis.

The company employs 22,000 workers across the globe.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The official website for the company is www.r1rcm.com. The healthcare provider can be reached via phone at (312) 324-7820, via email at arahim@r1rcm.com, or via fax at 302-655-5049.